Kiniksa Pharmaceuticals International, plc (KNSA)
Market: NASD |
Currency: USD
Address: 23 Old Bond Street
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Show more
📈 Kiniksa Pharmaceuticals International, plc Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$38.00
-
Upside/Downside from Analyst Target:
36.05%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
50-100%
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Kiniksa Pharmaceuticals International, plc
| Date | Reported EPS |
|---|
| 2025-04-29 | 0.11 |
| 2025-02-25 | -0.12 |
| 2024-10-29 | -0.18 |
| 2024-07-23 | -0.06 |
| 2024-07-22 | -0.06 |
| 2024-04-23 | -0.25 |
| 2024-04-22 | -0.25 |
| 2024-02-28 | 0.35 |
| 2024-02-27 | 0.35 |
| 2023-10-31 | -0.2 |
| 2023-10-30 | -0.2 |
| 2023-07-25 | 0.21 |
| 2023-07-24 | 0.21 |
| 2023-05-02 | -0.18 |
| 2023-05-01 | -0.18 |
| 2023-02-28 | 0.06 |
| 2023-02-27 | 0.06 |
| 2022-11-01 | 3.18 |
| 2022-10-31 | 3.18 |
| 2022-08-03 | -0.29 |
| 2022-08-02 | -0.29 |
| 2022-05-03 | -0.36 |
| 2022-05-02 | -0.36 |
| 2022-02-22 | -0.53 |
| 2022-02-21 | -0.53 |
| 2021-11-01 | -0.44 |
| 2021-10-31 | -0.44 |
| 2021-08-03 | -0.61 |
| 2021-08-02 | -0.61 |
| 2021-05-04 | -0.72 |
| 2021-05-03 | -0.72 |
| 2021-02-23 | -0.79 |
| 2021-02-22 | -0.79 |
| 2020-11-05 | -0.66 |
| 2020-11-04 | -0.66 |
| 2020-07-30 | -0.65 |
| 2020-07-29 | -0.65 |
| 2020-04-28 | -0.48 |
| 2020-04-27 | -0.48 |
| 2020-02-26 | -0.58 |
| 2020-02-25 | -0.58 |
| 2019-10-28 | -0.49 |
| 2019-10-27 | -0.49 |
| 2019-08-12 | -0.68 |
| 2019-08-11 | -0.68 |
| 2019-05-02 | -1.27 |
| 2019-05-01 | -1.27 |
| 2019-03-07 | -0.88 |
| 2019-03-06 | -0.88 |
| 2018-10-31 | -0.51 |
| 2018-08-05 | -0.97 |
| 2018-05-23 | - |
📰 Related News & Research
No related articles found for "kiniksa pharmaceuticals".
